QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kenneth-griffin-reports-999-passive-stake-in-spruce-biosciences-inc-as-of-oct-9

-SEC Filing

 reported-earlier-spruce-biosciences-reveals-500m-private-placement-financing

Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...

 spruce-biosciences-sprb-stock-jumps-30-after-hours-following-red-hot-rally-on-monday-heres-why

Spruce Biosciences shares soared after the FDA granted Breakthrough Therapy Designation to its lead treatment for Sanfilippo Sy...

 spruce-biosciences-stock-is-soaring-today-heres-why

Shares of Spruce Biosciences, Inc. (NASDAQ: SPRB) are surging Monday after the biotech company shared an important regulatory u...

 spruce-biosciences-says-fda-grants-breakthrough-therapy-designation-to-tralesinidase-alfa-enzyme-replacement-therapy-for-treatment-of-sanfilippo-syndrome-type-b

Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal...

 spruce-biosciences-to-resume-trading-on-nasdaq-capital-market-at-market-open-on-september-15-under-ticker-symbol-sprb

Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...

 spruce-biosciences-q2-eps-350-beats-1913-estimate

Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(3.50) per share which beat the analyst consensus estimate of $(...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION